

Inversion of the V δ 1 to V δ 2 $\gamma\delta$ T cell ratio in CVID is not restored by IVIg and is associated with immune activation and exhaustion

Dominic Paquin-Proulx, PhD^{a,*}, Nathália Silveira Barsotti, PhD^b, Bianca A. N. Santos, MSc^b, Ana Karolina B. B. Marinho, MD, PhD^b, Cristina M. Kokron, MD, PhD^b, Karina I. Carvalho, PhD^c, Myrthes T. Barros, MD, PhD^b, Jorge Kalil, MD, PhD^b, Douglas F. Nixon, MD, PhD^a, Esper G. Kallas, MD, PhD^b

Abstract

Common variable immunodeficiency (CVID) is defined by low levels of IgG and IgA, but perturbations in T cells are also commonly found. However, there is limited information on $\gamma\delta$ T cells in CVID patients. Newly diagnosed CVID patients ($n=15$) were enrolled before and after intravenous IgG (IVIg) replacement therapy. Cryopreserved peripheral blood mononuclear cells were then used to study $\gamma\delta$ T cells and CVID patients were compared to healthy controls ($n=22$). The frequency and absolute count of V δ 1 $\gamma\delta$ T cells was found to be increased in CVID (median 0.60% vs 2.64%, $P<0.01$ and 7.5 vs 39, $P<0.01$ respectively), while they were decreased for V δ 2 $\gamma\delta$ T cells (median, 2.36% vs 0.74%, $P<0.01$ and 37.8 vs 13.9, $P<0.01$ respectively) resulting in an inversion of the V δ 1 to V δ 2 ratio (0.24 vs 1.4, $P<0.001$). Markers of immune activation were elevated on all subsets of $\gamma\delta$ T cells, and HLA-DR expression was associated with an expansion of V δ 1 $\gamma\delta$ T cells ($r=0.73$, $P=0.003$). Elevated PD-1 expression was found only on V δ 2 $\gamma\delta$ T cells (median 1.15% vs 3.08%, $P<0.001$) and was associated with the decrease of V δ 2 $\gamma\delta$ T cells ($r=-0.67$, $P=0.007$). IVIg had no effect on the frequency of V δ 1 and V δ 2 $\gamma\delta$ T cells or HLA-DR expression, but alleviated CD38 expression on V δ 1 $\gamma\delta$ T cells (median MFI 965 vs 736, $P<0.05$). These findings suggest that immunological perturbations of $\gamma\delta$ T cells are a general feature associated with CVID and are only partially reversed by IVIg therapy.

Abbreviations: CVID = common variable immunod, DN = double negative, IVIg = intravenous immunoglobulin, PD-1 = Programmed Death 1.

Keywords: CVID, gamma delta T cells, immune activation, IVIg, PD-1, V δ 1, V δ 2

Editor: M. Scott Killian.

Author contributions: conceived and designed the experiments: DP-P, DFN, EGK. Performed the experiments: DP-P, NSB, BANS. Analyzed the data: DP-P, NSB, BANS. Contributed reagents/materials/analysis tools: AKBBM, CMK, MTB, KIC, JK, DFN, EGK. Wrote the paper: DP-P, DFN, EGK.

This work was partially supported by the National Institutes of Health grant of the District of Columbia Center for AIDS Research (P30AI087714 and P30AI117970), Fundação de Amparo a Pesquisa do Estado de São Paulo (04/15856-9/EGK and 2010/05845-0/EGK/DFN), CNPq/CAPES 056/2012 (DFN).

The authors have no conflicts of interest to disclose.

Supplemental Digital Content is available for this article.

^a Department of Microbiology, Immunology and Tropical Medicine, The George Washington University, Washington, DC, ^b Division of Clinical Immunology and Allergy, University of São Paulo School of Medicine, ^c Hospital Israelita Albert Einstein, Instituto Israelita de Ensino e Pesquisa, São Paulo, Brazil.

* Correspondence: Dominic Paquin-Proulx, Department of Microbiology, Immunology and Tropical Medicine, The George Washington University, Washington, DC 20037 (e-mail: dpaquin_proulx@gwu.edu).

Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially.

Medicine (2016) 95:30(e4304)

Received: 18 April 2016 / Received in final form: 23 June 2016 / Accepted: 28 June 2016

<http://dx.doi.org/10.1097/MD.0000000000004304>

1. Introduction

Common variable immunodeficiency (CVID) is characterized by low levels of IgG and IgA and/or IgM (2 standard deviations below the normal level) and by an impaired antibody response to vaccination.^[1] While some genetic mutations causing CVID have been identified, it is thought to be a polygenic disease with multiple susceptibility loci involved.^[2] The poor antibody response in CVID patients results in recurrent infections of the respiratory and gastrointestinal tracts. CVID patients also have an increased incidence of some forms of cancer and autoimmunity,^[3,4] probably due to the chronic state of immune activation and loss of key regulatory cells.^[5–8] Treatment for CVID consists of IgG replacement that can be given subcutaneous or intravenously (IVIg). Replacement therapy significantly reduces the number of infections^[9] and corrects some immune abnormalities,^[10] while other perturbations are only partially restored or unchanged.^[6]

In humans, $\gamma\delta$ T cells represent between 0.5% and 16% of T cells in the blood with an average of approximately 4%.^[11] The major subsets are designated V δ 1 and V δ 2, the latter being the most abundant. Similar to $\alpha\beta$ T cells, $\gamma\delta$ T cells develop in the thymus and undergo gene rearrangement, but they are not subjected to positive selection.^[12] They can produce similar cytokines to conventional $\alpha\beta$ T cells, including IL-17,^[13] and can also have cytotoxic functions. Following infection, $\gamma\delta$ T cells are activated earlier than $\alpha\beta$ T cells and are involved in the initiation of the inflammatory response.^[11] The antigens recognized by $\gamma\delta$

T cells are very diverse and include phosphoantigens, peptides, and glycolipids.^[11,14] The $\gamma\delta$ TCR can also recognize stress-induced ligands. For instance, a V γ 4V δ 5 T cell clone has been shown to recognize EPCR expression on tumor cell and CMV-infected cells.^[15]

HIV infection leads to a profound perturbation of the $\gamma\delta$ T cells population,^[16] characterized by an early expansion of the V δ 1 T cells, while V δ 2 T cells are greatly reduced in number.^[17] V δ 2 T cells from HIV patients were also found to have a lower capacity to respond to phosphoantigens.^[18] The expansion of V δ 1 T cells has been associated with increased microbial translocation,^[19] now recognized as a major contributor of chronic immune activation in HIV infection.^[20] CVID patients share several immunological features with HIV patients, namely CD4⁺ and CD8⁺ T cell activation, loss of iNKT cells and of regulatory T cells.^[5,6] In contrast to CVID, HIV is characterized by hypergammaglobulinemia, but HIV disease progression is characterized by loss of memory B cell subsets and impaired antibody response to vaccination.^[21,22] Increased microbial translocation has also been suggested to occur in CVID.^[23] Two case report studies have shown an increase in $\gamma\delta$ T cells in 1 CVID patient each^[24,25]; however, no $\gamma\delta$ T cells study has been performed on a larger cohort of CVID patients. We hypothesized that chronic immune activation in CVID patients would lead to perturbations in $\gamma\delta$ T cells populations. Thus, we evaluated the frequency and phenotype of $\gamma\delta$ T cells in a cohort of CVID patients.

2. Materials and methods

2.1. Study cohort and samples

Fifteen CVID patients (10 females and 5 males aged 6–51, average 34) from the Primary Immunodeficiency Outpatient Clinic of Clinical Immunology and Allergy Division of HC-FMUSP, fulfilling the PAGID/ESID criteria (1999) for CVID diagnosis and 22 healthy controls (14 females, 8 males aged 25–45, average 36) were enrolled in the study. Group size was based on sample availability. All patients were HIV negative. The study was approved by the Hospital das Clínicas, University of São Paulo Medical School Ethics Committee (CAPPesq), and written informed consent was provided by all participants or their legal guardians. Peripheral blood mononuclear cells (PBMC) were isolated by density-gradient sedimentation using Ficoll-Paque (Lymphoprep; Nycomed Pharma, Oslo, Norway). Isolated PBMC were washed twice in Hank balanced salt solution (Gibco, Grand Island, NY), and cryopreserved in RPMI 1640 (Gibco), supplemented with 20% heat inactivated fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT), 50 U/mL of penicillin (Gibco), 50 μ g/mL of streptomycin (Gibco), 10 mM glutamine (Gibco) and 7.5% dimethylsulphoxide (DMSO; Sigma, St Louis, MO). Cryopreserved PBMC from all subjects were stored in liquid nitrogen until used in the assays. For CVID patients, samples were collected before and after initiation of IVIg treatment.

2.2. Flow cytometry and mAbs

Cryopreserved specimens were thawed, washed, and counts and viability were assessed using the Countess Automated Cell Counter system (Invitrogen, Carlsbad, CA). PBMC were washed and stained in Brilliant Violet Stain Buffer (BD Biosciences, San Jose, CA) at room temperature for 15 min in 96-well V-bottom

plates in the dark. Samples were then washed and fixed using Cytofix/Cytoperm (BD Biosciences) before flow cytometry data acquisition. mAbs used in flow cytometry; CD3 AF700 (clone UCHT1), CD4 PE-CF594 (clone RPA-T4), CD8 BV711 (clone RPA-T8), CD38 APC-H7 (clone HB7), CD161 BV421 (clone DX12), HLA-DR APC (clone L243), TCR $\gamma\delta$ BV650 (clone B1), and PD-1 PE-Cy7 (clone EH12.1) were all from BD Biosciences, TCR V δ 1 FITC (clone TS8.2) was from Abcam (Cambridge, MA), and TCR V δ 2 PE (clone B6) was from Biolegend (San Diego, CA). Live/dead aqua fixable cell stain was from Life Technologies (Eugene, OR). All antibodies were used together in 1 panel. A minimum number of 200 events were recorded for all subsets of $\gamma\delta$ T cells. Data were acquired on a BD LSRFortessa instrument (BD Biosciences) and analyzed using FlowJo Version 9.8.5 software (TreeStar, Ashland, OR).

2.3. Statistical analysis

All statistical analyses were performed using Graph Pad Prism version 6.0f for Mac OSX (GraphPad Software, La Jolla, CA). The comparison between healthy controls and CVID patients was analyzed using Mann–Whitney *U* test and changes after IVIg initiation in CVID patients were analyzed with Wilcoxon matched-pairs signed rank test. Nonparametric analyses were performed because the data were not normally distributed. Associations between groups were determined by Spearman rank correlation. *P* values <0.05 were considered statistically significant.

3. Results

3.1. Expansion of V δ 1⁺ and loss of V δ 2⁺ in CVID

Table 1 shows the demographic details of the subjects included in this study. We used cryopreserved PBMCs samples from a treatment naive cohort of CVID patients followed 9 to 15 months after initiation of monthly intravenous immunoglobulin replacement therapy (400–600 mg/k) to study $\gamma\delta$ T cells by flow cytometry. The viability of the thawed PBMC was over 95% and there was no difference in the viability between the groups. First, we evaluated the frequency of the V δ 1⁺, V δ 2⁺, and V δ 1[−] V δ 2[−] $\gamma\delta$ ⁺ subsets in healthy controls and in treatment naive CVID patients. In healthy controls, V δ 1⁺ cells typically represented less than 1% of the T cells and V δ 2⁺ represented the major subset of $\gamma\delta$ T cells (Supplementary file 1, <http://links.lww.com/MD/B140>). Supplementary file 2, <http://links.lww.com/MD/B141> summarized all comparisons between CVID patients and healthy controls. In CVID patients V δ 1⁺ were significantly increased (median 0.60% vs 2.64%, *P*<0.01) while V δ 2⁺ were reduced (median, 2.36% vs 0.74%, *P*<0.01) compared with healthy controls (Fig. 1A). The frequency of the V δ 1[−] V δ 2[−] $\gamma\delta$ ⁺ subsets was also increased in CVID patients (Fig. 1A, median 0.39% vs 0.59%, *P*<0.05). Overall, this led to a significant increase in the ratio of V δ 1⁺ to V δ 2⁺ (Fig. 1B, 0.24 vs 1.4, *P*<0.001). Importantly, the frequency of all subsets of $\gamma\delta$ T cells was not changed after IgG replacement therapy (median 2.64% vs 5.25%, *P*=0.17; 0.74% vs 1.33% *P*=0.58; 0.59% vs 0.60%, *P*=0.21 for V δ 1⁺, V δ 2⁺, and V δ 1[−] V δ 2[−] $\gamma\delta$ ⁺ T cell respectively).

Next, we compared the absolute count of each subset of $\gamma\delta$ T cells in CVID patients to those observed in healthy controls. Again, V δ 1⁺ were increased (median 7.5 vs 39, *P*<0.01) and V δ 2⁺ were decreased (median 37.8 vs 13.9, *P*<0.01; Fig. 1B). However, the absolute count of V δ 1[−] V δ 2[−] $\gamma\delta$ ⁺ was normal in

Table 1
Subjects demographics.

	Gender	Age	CD3 (cell/ μ L)	IgG (mg/mL)	IgA (mg/mL)	IgM (mg/mL)
CVID 1	M	32	1118	63	<25	<12.5
CVID 2	F	27	1028	NA	NA	NA
CVID 3	M	24	2373	2	3.7	0.7
CVID 4	F	25	1172	440	2.8	3.4
CVID 5	F	31	1523	273	0.6	63.8
CVID 6	F	31	2184	59	<25	167.7
CVID 7	F	6	NA	NA	NA	NA
CVID 8	F	31	1843	<300	<50	<25
CVID 9	M	41	2480	<300	<50	<25
CVID 10	F	40	2985	<300	<50	<25
CVID 11	F	34	1092	<300	<50	33.1
CVID 12	M	34	1148	98	<50	<25
CVID 13	F	51	1077	86	4	4
CVID 14	F	35	2623	79	<50	25.9
CVID 15	M	62	781	69	<50	<25
CTRL 1	M	28	911	NA	NA	NA
CTRL 2	F	25	1678	NA	NA	NA
CTRL 3	M	36	NA	NA	NA	NA
CTRL 4	M	36	2226	NA	NA	NA
CTRL 5	M	30	1991	NA	NA	NA
CTRL 6	F	41	2003	NA	NA	NA
CTRL 7	F	28	1695	NA	NA	NA
CTRL 8	F	31	877	NA	NA	NA
CTRL 9	F	33	1407	NA	NA	NA
CTRL 10	F	38	1912	NA	NA	NA
CTRL 11	M	59	1652	NA	NA	NA
CTRL 12	F	63	1932	NA	NA	NA
CTRL 13	F	64	1254	NA	NA	NA
CTRL 14	F	17	1763	NA	NA	NA
CTRL 15	F	35	1712	NA	NA	NA
CTRL 16	M	45	NA	NA	NA	NA
CTRL 17	F	25	NA	NA	NA	NA
CTRL 18	M	21	4420	NA	NA	NA
CTRL 19	M	37	4938	NA	NA	NA
CTRL 20	F	33	1875	NA	NA	NA
CTRL 21	F	33	1428	NA	NA	NA
CTRL 22	F	30	1330	NA	NA	NA

CVID patients (median 7.3 vs 9.5, $P=0.69$; Fig. 1B). The absolute count of all subsets of $\gamma\delta$ T cells was not affected by IVIg (median, 39 vs 78.3 $P=0.81$; 13.9 vs 23.9, $P=0.58$; 9.5 vs 7.9 $P=0.69$ for $V\delta 1^+$, $V\delta 2^+$, and $V\delta 1^- V\delta 2^- \gamma\delta^+$ T cell respectively). Thus, our results suggest a specific expansion of $V\delta 1^+$ and loss of $V\delta 2^+$ subsets in CVID.

3.2. Differential redistribution of $CD4^+$ and $CD8^+$ on $\gamma\delta$ T cells in CVID

We evaluated the distribution of CD4 and CD8 expression on $\gamma\delta$ T cells for each of the $\gamma\delta$ T cells subsets individually. As expected, the major population for all subsets of $\gamma\delta$ T cells was double negative (DN). CD4 expression was reduced for $V\delta 1^+$ and $V\delta 1^- V\delta 2^- \gamma\delta^+$ T cells in CVID (median 11.6% vs 1.74%, $P<0.01$; 27.5% vs 8.04%, $P<0.001$ respectively; Fig. 2A). $V\delta 1^+$ presented an increased DN population while the CD8 population was increased for $V\delta 1^- V\delta 2^- \gamma\delta^+$ (median 45.5% vs 64.4%, $P<0.01$; 29.6% vs 32.4%, $P<0.05$; Fig. 2B and C). On the other hand, CD4 and CD8 expression was normal on $V\delta 2^+$ cells (median 2.62% vs 3.12%, $P=0.96$; 29.6% vs 32.4%, $P=0.4$ respectively). Expression of CD4 and CD8 on all subsets of $\gamma\delta$ T

cells was not changed after IVIg. Thus, our results show that $\gamma\delta$ T cells subsets in CVID have differential distribution of CD4 and CD8 expression.

3.3. High levels of $\gamma\delta$ T cells activation in CVID

CVID is characterized by elevated $CD4^+$ and $CD8^+$ T cell activation,^[6] therefore, we hypothesized that $\gamma\delta$ T cells also had high levels of activation. We observed elevated levels of CD38, HLA-DR and coexpression of CD38 and HLA-DR on $V\delta 1^+$ (median MFI 576 vs 965, $P<0.001$; 44.9% vs 73.1%, $P<0.01$; 30.5% vs 50.3%, $P<0.001$ respectively), $V\delta 2^+$ (median MFI 99.1 vs 299, $P<0.01$; 18.1% vs 44.9%, $P<0.01$; 8.41% vs 17.2%, $P<0.001$ respectively), and $V\delta 1^- V\delta 2^- \gamma\delta^+$ T cells (median MFI 652 vs 968, $P<0.01$; 43.7% vs 65.6%, $P<0.01$; 26.1% vs 49%, $P<0.001$ respectively, Fig. 3A–C) confirming our hypothesis. Following replacement therapy CD38 levels and CD38 and HLA-DR coexpression were reduced only on $V\delta 1^+$ (median MFI 965 vs 736, $P<0.001$; 50.3% vs 38.3%, $P<0.05$ respectively; Fig. 3A and C) but remained higher compared with healthy controls (median MFI 576 vs 736, $P<0.05$; 30.5% vs 38.3%, $P<0.05$ respectively).




Figure 1. Inverted V $\delta 1^+$ /V $\delta 2^+$ ratio in CVID. Frequency of V $\delta 1^+$, V $\delta 2^+$, V $\delta 1^-$ V $\delta 2^-$ $\gamma \delta^+$ T cells (A), V $\delta 1^+$ /V $\delta 2^+$ ratio (B), and absolute count of V $\delta 1^+$, V $\delta 2^+$, and V $\delta 1^-$ V $\delta 2^-$ $\gamma \delta^+$ T cells (C) in healthy controls, treatment naive, and IVg-treated CVID patients. * indicates $P < 0.05$, the lines and whiskers represent the median and interquartile range respectively. CVID = common variable immunod, IVg = intravenous immunoglobulin.

3.4. Elevated PD-1 expression by V $\delta 2^+$ T cells in CVID

Programmed death 1 (PD-1) is an inhibitory receptor and its expression is associated with immune exhaustion in chronic infections.^[26] We have previously reported that PD-1 expression is elevated on CD4⁺ T cells in CVID.^[6] Thus, we investigated PD-1 expression by $\gamma \delta^+$ T cells in CVID. We observed that PD-1 expression was normal on V $\delta 1^+$ and V $\delta 1^-$ V $\delta 2^-$ $\gamma \delta^+$ T cells (median, 33.0% vs 43.0%, $P = 0.22$; 33.9% vs 32.7%, $P = 0.88$ respectively) but elevated on V $\delta 2^+$ (median 1.15% vs 3.08%, $P < 0.001$; Fig. 4A). PD-1 remained elevated on V $\delta 2^+$ after immune reconstitution (median 1.15% vs 3.09%, $P < 0.001$) but was reduced on V $\delta 1^+$ (median 43.0% vs 36.5%, $P < 0.05$).

3.5. Activation and exhaustion are associated with $\gamma \delta$ T cells frequency in CVID

Finally, we investigated if the elevated levels of activation and exhaustion could be associated with the change in $\gamma \delta$ T cells frequency that we observed. HLA-DR expression was positively associated with the frequency of V $\delta 1^+$ and V $\delta 1^-$ V $\delta 2^-$ $\gamma \delta^+$ T cells ($r = 0.73$, $P = 0.003$; $r = 0.68$, $P = 0.006$ respectively; Fig. 5A and B) but not with V $\delta 2^+$ T cell frequency ($r = 0.022$, $P = 0.94$; Fig. 5C) in treatment naive CVID patients. V $\delta 2^+$ T cell frequency was negatively associated with PD-1 expression ($r = -0.67$, $P = 0.007$; Fig. 5D).

4. Discussion

Previous case reports described an expansion of $\gamma \delta$ T cells in 2 CVID patients and this expansion was associated with *Mycobacterium* infection for one of them.^[24,25] Our findings now suggest that perturbations in $\gamma \delta$ T cells are a general feature of CVID patients. We observed an increase of V $\delta 1^+$ and a decrease of V $\delta 2^+$ $\gamma \delta$ T cells in CVID, leading to an inversion of the V $\delta 1^+$ to V $\delta 2^+$ $\gamma \delta$ T cell ratio. Interestingly, the majority of sulfatide reactive type II NKT cells have been described to express V $\delta 1$,^[27] however it remains to be determined if this population of type II NKT cells is expanded in CVID patients together with V $\delta 1^+$ $\gamma \delta$ T cells or reduced like type I NKT cells.^[28,29]

V $\delta 2^+$ $\gamma \delta$ T cells are known to interact with many immune cells to shape immune responses, including B cells to stimulate humoral immunity^[30] and activated V $\delta 2^+$ $\gamma \delta$ T cells have been shown to act as antigen-presenting cells.^[31,32] Furthermore, V $\delta 2^+$ T cells can recognize mevalonate metabolites in tumor cells and are believed to have an important antitumor activity.^[33] Therefore, loss of this cell population could partially explain some of the immunological perturbation seen in CVID and the increased incidence of some forms of cancer. More studies are required to determine if the reduced frequency of V $\delta 2^+$ $\gamma \delta$ T cells in the blood of CVID patients is due to redistribution to tissues or to a complete loss of those cells. More studies are also needed to evaluate the functionality of the remaining V $\delta 2^+$ $\gamma \delta$ T cells. A mutation in Vav1 has been associated with impaired Th2




Figure 2. Altered CD4 and CD8 expression on $\gamma\delta$ T cells in CVID. Proportion of $\gamma\delta^+$ T cells expressing CD4 (A), CD8 (B), or DN (C) in healthy controls, treatment naive, and IVIg-treated CVID patients. * indicates $P < 0.05$, the lines and whiskers represent the median and interquartile range respectively.




Figure 3. Elevated $\gamma\delta$ T cells activation in CVID. CD38 MFI (A), levels of HLA-DR (B), and coexpression of CD38 and HLA-DR (C) by $\gamma\delta^+$ T cells in healthy controls, treatment naive, and IVIg-treated CVID patients. * indicates $P < 0.05$, the lines and whiskers represent the median and interquartile range respectively.

response in a subset of CVID patients,^[34,35] more experiments are needed to assess the impact of this mutation on $\gamma\delta$ T cell functionality.

The high levels of activation of all subsets of $\gamma\delta$ T cells that we report here were not affected by IVIg treatment, suggesting that IVIg is not controlling the factors responsible for $\gamma\delta$ T cells activation. However, it is possible that a longer period of time on replacement therapy is needed to observe a reduction in $\gamma\delta$ T cells activation. There is now accumulating evidence that IgG replacement does not restore a normal immune system in CVID. Complementary therapies aiming to restore normal cellular immunity should be considered and could prevent some of the complications associated with CVID. Long-term low-dose IL-2 has been shown to enhance T cell function in CVID patients^[36] but other compartments of the cellular immune system were not studied.

Interestingly, the expansion of V $\delta 1^+$ and the reduction in V $\delta 2^+$ $\gamma\delta$ T cells in CVID is similar to that which has been described for




Figure 4. Expression of PD-1 by $\gamma\delta$ T cells in CVID. Levels of PD-1 expression by $\gamma\delta^+$ T cells (A) in healthy controls, treatment naive, and IVIg-treated CVID patients. * indicates $P < 0.05$, the lines and whiskers represent the median and interquartile range respectively. PD-1 = Programmed Death 1.




Figure 5. Associations between activation, exhaustion, and $\gamma\delta$ T cells subsets frequency in CVID. Correlation between HLA-DR expression and $V\delta 1^+$ (A), $V\delta 1^- V\delta 2^- \gamma\delta^+$ (B), $V\delta 2^+$ (C) T cells frequency in treatment naive CVID patients. Correlation between PD-1 expression and $V\delta 2^+$ T cells frequency in treatment naive CVID patients (D).

HIV infection,^[16] suggesting that common drivers in the pathology associated with primary and secondary immunodeficiency might exist. In this regard, microbial translocation has been implicated in the inversion of the $V\delta 1^+$ to $V\delta 2^+$ ratio in SIV infection^[19] and in CD4 T cell exhaustion in CVID.^[23] Expansion of $V\delta 1^+$ and $V\delta 1^- V\delta 2^- \gamma\delta^+$ T cells in CVID was associated with activation, suggesting an implication for chronic inflammation in expending those subsets of $\gamma\delta$ T cells. Therefore, we propose that inversion of the $V\delta 1$ to $V\delta 2$ ratio in CVID is a reflection of the infection burden.

Altogether, our results suggest that IVIg replacement therapy is not sufficient to normalize change in $\gamma\delta$ T cells frequency and activation in CVID. Furthermore, our results add to the list of similarities between primary and secondary immunodeficiencies, such as HIV infection.

Acknowledgments

The authors thank all patients and healthy controls for their time and efforts toward this study. The authors thank Carla Alves for her support in the laboratory work.

References

- [1] Park MA, Li JT, Hagan JB, et al. Common variable immunodeficiency: a new look at an old disease. *Lancet* 2008;372:489–502.
- [2] van Schouwenburg PA, Davenport EE, Kienzler AK, et al. Application of whole genome and RNA sequencing to investigate the genomic landscape of common variable immunodeficiency disorders. *Clin Immunol* 2015; 160:301–14.
- [3] Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. *Clin Immunol* 1999;92:34–48.
- [4] Resnick ES, Moshier EL, Godbold JH, et al. Morbidity and mortality in common variable immune deficiency over 4 decades. *Blood* 2012;119: 1650–7.
- [5] Paquin-Proulx D, Sandberg JK. Persistent immune activation in CVID and the role of IVIg in its suppression. *Front Immunol* 2014;5:637.
- [6] Paquin-Proulx D, Santos BA, Carvalho KI, et al. IVIg immune reconstitution treatment alleviates the state of persistent immune activation and suppressed CD4 T cell counts in CVID. *PLoS One* 2013;8:e75199.
- [7] Vlkova M, Ticha O, Nechvatlova J, et al. Regulatory B cells in CVID patients fail to suppress multifunctional IFN-gamma+ TNF-alpha+ CD4+ T cells differentiation. *Clin Immunol* 2015;160: 292–300.
- [8] Barsotti NS, Almeida RR, Costa PR, et al. IL-10-producing regulatory B cells are decreased in patients with common variable immunodeficiency. *PLoS One* 2016;11:e0151761.
- [9] Duraisingham SS, Buckland M, Dempster J, et al. Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement. *PLoS One* 2014;9:e100324.
- [10] Paquin-Proulx D, Santos BA, Carvalho KI, et al. Dysregulated CD1 profile in myeloid dendritic cells in CVID is normalized by IVIg treatment. *Blood* 2013;121:4963–4.
- [11] Chien YH, Meyer C, Bonneville M. gammadelta T cells: first line of defense and beyond. *Annu Rev Immunol* 2014;32:121–55.
- [12] Schweighoffer E, Fowlkes BJ. Positive selection is not required for thymic maturation of transgenic gamma delta T cells. *J Exp Med* 1996;183: 2033–41.
- [13] Haas JD, Ravens S, Duber S, et al. Development of interleukin-17-producing gammadelta T cells is restricted to a functional embryonic wave. *Immunity* 2012;37:48–59.
- [14] Adams EJ, Gu S, Luoma AM. Human gamma delta T cells: evolution and ligand recognition. *Cell Immunol* 2015;296:31–40.

- [15] Willcox CR, Pitard V, Netzer S, et al. Cytomegalovirus and tumor stress surveillance by binding of a human gammadelta T cell antigen receptor to endothelial protein C receptor. *Nat Immunol* 2012;13:872–9.
- [16] Pauza CD, Poonia B, Li H, et al. Gammadelta T cells in HIV disease: past, present, and future. *Front Immunol* 2014;5:687.
- [17] De Paoli P, Gennari D, Martelli P, et al. A subset of gamma delta lymphocytes is increased during HIV-1 infection. *Clin Exp Immunol* 1991;83:187–91.
- [18] Wallace M, Scharko AM, Pauza CD, et al. Functional gamma delta T-lymphocyte defect associated with human immunodeficiency virus infections. *Mol Med* 1997;3:60–71.
- [19] Harris LD, Klatt NR, Vinton C, et al. Mechanisms underlying gammadelta T-cell subset perturbations in SIV-infected Asian rhesus macaques. *Blood* 2010;116:4148–57.
- [20] Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat Med* 2006;12:1365–71.
- [21] Titanji K, De Milito A, Cagigi A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. *Blood* 2006;108:1580–7.
- [22] Hart M, Steel A, Clark SA, et al. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. *J Immunol* 2007;178:8212–20.
- [23] Perreau M, Vigano S, Bellanger F, et al. Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders. *J Exp Med* 2014;211:2033–45.
- [24] Viallard JF, Bloch-Michel C, Caubet O, et al. Gammadelta T lymphocytosis associated with granulomatous disease in a patient with common variable immunodeficiency. *Clin Infect Dis* 2002;35:e134–137.
- [25] Katial RK, Lieberman MM, Muehlbauer SL, et al. Gamma delta T lymphocytosis associated with common variable immunodeficiency. *J Clin Immunol* 1997;17:34–42.
- [26] Khaitan A, Unutmaz D. Revisiting immune exhaustion during HIV infection. *Curr HIV/AIDS Rep* 2011;8:4–11.
- [27] Bai L, Picard D, Anderson B, et al. The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vdelta1 TCR. *Eur J Immunol* 2012;42:2505–10.
- [28] Carvalho KI, Melo KM, Bruno FR, et al. Skewed distribution of circulating activated natural killer T (NKT) cells in patients with common variable immunodeficiency disorders (CVID). *PLoS One* 2010;5:e12652.
- [29] Fulcher DA, Avery DT, Fewings NL, et al. Invariant natural killer (iNK) T cell deficiency in patients with common variable immunodeficiency. *Clin Exp Immunol* 2009;157:365–9.
- [30] Tyler CJ, Doherty DG, Moser B, et al. Human Vgamma9/Vdelta2 T cells: innate adaptors of the immune system. *Cell Immunol* 2015;296:10–21.
- [31] Brandes M, Willmann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. *Science* 2005;309:264–8.
- [32] Muto M, Baghdadi M, Maekawa R, et al. Myeloid molecular characteristics of human gammadelta T cells support their acquisition of tumor antigen-presenting capacity. *Cancer Immunol Immunother* 2015;64:941–9.
- [33] Gober HJ, Kistowska M, Angman L, et al. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. *J Exp Med* 2003;197:163–8.
- [34] Capitani N, Ariani F, Amedei A, et al. Vav1 haploinsufficiency in a common variable immunodeficiency patient with defective T-cell function. *Int J Immunopathol Pharmacol* 2012;25:811–7.
- [35] Capitani N, Amedei A, Paccani SR, et al. Impaired TH2 response in patients with Vav1-deficient common variable immunodeficiency with T-cell defects. *J Allergy Clin Immunol* 2010;126:671–5.
- [36] Cunningham-Rundles C, Bodian C, Ochs HD, et al. Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency. *Clin Immunol* 2001;100:181–90.